Prelude Capital Management, LLC Gain Therapeutics, Inc. Transaction History
Prelude Capital Management, LLC
- $1.57 Billion
- Q3 2024
A detailed history of Prelude Capital Management, LLC transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Prelude Capital Management, LLC holds 35,820 shares of GANX stock, worth $61,610. This represents 0.0% of its overall portfolio holdings.
Number of Shares
35,820
Previous 35,820
-0.0%
Holding current value
$61,610
Previous $63,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding GANX
# of Institutions
23Shares Held
2.39MCall Options Held
10KPut Options Held
0-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$1.01 Million0.1% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$973,7430.04% of portfolio
-
Joel Greenblatt Gotham Asset Management, LLC | New York, Ny335KShares$575,4980.01% of portfolio
-
Geode Capital Management, LLC Boston, MA272KShares$467,7910.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA145KShares$249,7730.0% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $20.4M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...